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A B S T R A C T
Purpose: Sudden unexplained death in epilepsy (SUDEP) is uncommon. Discussing the risk of SUDEP can
be difﬁcult, particularly in those where the risk is considered low, and previous studies have suggested
that clinical practice varies widely. The Scottish Intercollegiate Guidelines Network (SIGN) suggest
information on SUDEP is ‘‘essential’’ and National Institute of Clinical Excellence (NICE) recommend that
‘‘tailored information on the person’s relative risk of SUDEP should be part of the counselling process. . .’’.
The study aimed to evaluate if discussion of SUDEP risk is being documented in clinical records and to
determine if there is an association between documented discussion and risk factors for SUDEP.
Methods: A retrospective case note review was undertaken in those with an established diagnosis of
epilepsy attending clinic between 1st January 2009 and 30th June 2009.
Results: Overall, a documented SUDEP discussion was noted in 14/345 (4%) cases. Patients were
statistically more likely to have a documented SUDEP discussion if they had ongoing generalised tonic-
clonic seizures, with a trend also towards informing those non-compliant with medication.
Conclusion: Patients were more likely to be informed of SUDEP if they had potentially modiﬁable risk
factors identiﬁed. There was, however, no documented evidence to suggest that SUDEP is being
discussed in the majority of cases.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy affects approximately 40,000 people in Scotland. Each
year approximately 100 people from this population will die from
an epilepsy-related death.1 Sudden unexpected death is deﬁned as
the: ‘‘Sudden, unexpected, witnessed or unwitnessed, nontraumatic
and nondrowning death in patients with epilepsy, with or without
evidence for a seizure and excluding documented status epilepticus, in
which postmortem examination does not reveal a toxicologic or
anatomic cause for death.’’2 Post-mortem studies indicate that up to
60% of all epilepsy-related deaths can be accounted for by SUDEP,3
making it the single most common cause of mortality in epilepsy.
The Scottish Intercollegiate Guidelines Network (SIGN) state
that the provision of information on SUDEP is ‘essential’ to newly
diagnosed patients.4 Further to this, a fatal accident inquiry (FAI) in
2002 into a SUDEP-related death concluded that: ‘‘..in the vast
majority of cases there should be a discussion’’ regarding SUDEP with
patients. A further FAI in 2011 into two SUDEP-related deaths* Corresponding author at: Department of Neurology, Ninewells Hospital,
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http://dx.doi.org/10.1016/j.seizure.2012.09.017concluded that: ‘‘The vast majority of patients with epilepsy. . . should
be advised of the risk of SUDEP’’ unless deﬁned exclusion criteria are
met.5 These conclusions, although not legally binding, reﬂect
available guidelines and advocacy groups are in support of these
recommendations.6
There has, however, been discrepancy between these guidelines
and practice, with the National Sentinel Clinical Audit of Epilepsy
related Deaths ﬁnding that only 1% of those who died from SUDEP
in England and Wales had documented evidence of SUDEP
discussion in their secondary care notes.3 Further to this Morton
et al. found that only 5% of British Neurologists would inform all
patients of SUDEP,7 with similar ﬁndings from other European
countries.8
With this discrepancy between guidelines and practice and the
limitations of previous studies due to selection bias3 and self
reported practice7,8 we aimed to design and carry out an audit
which gives some insight into current clinical practice in a large
tertiary centre.
2. Methods
All patients who attended a specialist epilepsy clinic (inclusive
of all consultant, trainee and nurse-led appointments) between 1st
January 2009 and 30th June 2009 in Tayside were entered into thevier Ltd. All rights reserved.
Table 1
Risk factor: probability of SUDEP discussion.
Risk factor SUDEP discussion p value
Male gender 7/175 (4%) 1.00
<16 years old at onset 4/135 (3.0%) 0.27
Duration of epilepsy 15 years 4/163 (2.5%) 0.18
1 Generalised tonic-clonic (GTC)
seizures per year
11/128 (8.6%) 0.05
Drug resistancea 2/136 (1.5%) 0.05
Learning difﬁculties 1/60 (1.7%) 0.48
Non-complianceb 3/29 (10%) 0.07
a Deﬁned as unsuccessful trials of 2 antiepileptic medications at therapeutic
doses.
b Deﬁned as patient admission to non-compliance with medication as
prescribed.
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identify all patients who had had at least 2 unprovoked seizures,
thereby fulﬁlling the diagnostic criteria for epilepsy. A 5 year
retrospective case note analysis was then performed to: (1)
determine if there was documented evidence of SUDEP discussion
and (2) identify risk factors for SUDEP in each case.9,10
Descriptive statistics were used for risk factors and Fisher’s 2-
tailed test was used for comparison between risk factor groups.
3. Results
3.1. Basic demographics
Six hundred and two patients were seen in clinic; 367 fulﬁlled
the criteria for epilepsy (new referrals = 97; reviews = 270). Three
hundred and forty ﬁve case notes were available for review. The
mean age at review was 41.4 years and 175 (50.7%) were male.
3.2. Clinical characteristics
Forty-nine percent of patients had cryptogenic epilepsy, 16%
idiopathic epilepsy, 13% symptomatic and 21% had another type.
The predominant seizure type in the majority of cases was
generalised tonic-clonic seizures (43%), 35% had complex partial
seizures, 15% simple partial seizures, and 8% had another
predominant type, including myoclonic and absence seizures.
3.3. Documented SUDEP discussion
In 14 patients (4%) a documented discussion of SUDEP in the
last 5 years was recorded; a subgroup analysis of risk factors
identiﬁed in this group is shown in Fig. 1. Cross tabulation of the
probability of SUDEP discussion occurring in all those with
identiﬁed risk factors for SUDEP is demonstrated in Table 1.
4. Discussion
There is little evidence from this single tertiary centre study
that the risk of SUDEP is being discussed with the vast majority of
patients. Our current practice is consistent with previous studies
but is at odds with the recommendations of both SIGN4 and NICE.11
Despite the small numbers informed of SUDEP two factors
signiﬁcantly inﬂuenced the likelihood of SUDEP discussion
occurring: those with ongoing generalised seizures were more
likely to be informed and those with drug resistant seizures were
less likely to be informed. Further to this there was also a trend
towards discussing SUDEP with those non-compliant with
medication. This suggests that patients are more likely to be told
if they have potentially modiﬁable risk factors for SUDEP
identiﬁed. This association has not been previously reported.Fig. 1. SUDEP informed group: risk factors (n = 14).There are a number of factors which may underestimate the
true number of informed patients. It may be speculated that the
risk was discussed but not documented and similarly that
discussion was documented in contemporaneous handwritten
clinic notes but not in their audited clinic letter. It may also be
that chronic patients had been informed greater than 5 years
ago or that that patients may have received written information
regarding SUDEP from another source. It is impossible to predict
the number of patients in whom SUDEP was discussed but
where the discussion was not documented. The majority had
both handwritten entries and electronic clinic letters reviewed,
however in some only clinic letters were available. There were
no instances when discussion of SUDEP was documented in one
source but not the other. There is no consensus on how often
patients should be informed, although 5 years was considered
‘good practice’. Whilst it was not routine practice over the
period of audit to distribute written information on SUDEP,
some of the patients attending the epilepsy specialist nurse for
the 1st time may have been provided with such information
which was not documented; the total number of patients with
such contact was 34.
Another important issue is what information a clinician must
provide before it is considered the patient is fully informed. It may
be argued that ‘serious harm’ could be a surrogate term for death
and therefore this may have been discussed in preference of
SUDEP. In an additional 13 patients the term serious harm was
documented in the medical records. If these factors are taken into
consideration, assuming that ‘serious harm’ is an acceptable
alternative term to SUDEP, and that all those who met the epilepsy
specialist nurse were given written information, the total
informed would only increase from 4% to 17% of our clinic
population.
In general the audit is a reasonably robust reﬂection of local
clinical practice. It is unclear whether the data is generalisable
to the UK as a whole but is consistent with previous self
reported practice by members of the ABN. It is unlikely that
our data was subject to selection bias as the majority of patients
would be reviewed during a 6-month period and 94% of all
case notes were available for review. A further cycle of the
audit loop is planned and it will be interesting to determine
whether clinical practice has changed in the light of the recent
FAI.
Overall the low number of patients in whom SUDEP was
discussed is perhaps not surprising given the results from previous
publications. Much debate has been generated about the discus-
sion of SUDEP with patients. Advocacy groups and guidelines,
generated from medical opinion, are clear that all should be told,
however concern has been raised from the medical community
that a ‘one-size ﬁts all’ approach is not appropriate for SUDEP
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informing those with drug resistant epilepsy with a high but non-
modiﬁable risk of SUDEP will undermine a patient’s ‘right not to
know’ and cause unnecessary distress. Conversely, academic
debate has failed to reach a conclusion as to whether it is ethically
right to inform all or only those with risk factors for SUDEP.12
Without evidence that informing patients will lower SUDEP
incidence, or that discussion could cause harm to patients, these
theories remain speculative. It is then less surprising still that with
these unresolved issues that the majority of our patients were not
being informed of SUDEP.
In the absence of overwhelming evidence to suggest that
clinical practice changes outcomes, clinicians are likely to
consider the risk of SUDEP and balance this with the perceived
risk of causing unnecessary anxiety on a case to case basis.
The remit of this study was simply to evaluate actual clinic
practice and further studies are required to explore further why
SUDEP is currently being discussed in only the minority of
patients. An honest and frank debate is required between
clinicians, patient advocacy groups and those involved in
developing guidelines to allow one to reconcile the disparity
between guidelines and clinical practice with regard to
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